PTCT - PTCセラピュ―ティクス (PTC Therapeutics Inc.)

PTCTのニュース

   Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi in RAINBOWFISH  2021/06/11 05:00:00 Business Insider Markets
SOUTH PLAINFIELD, N.J., June 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomatic infants with spinal muscular atrophy (SMA) treated with
   Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi in RAINBOWFISH  2021/06/11 00:00:00 BioSpace
PTC Therapeutics, Inc. announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomatic infants with spinal muscular atrophy treated with Evrysdi were able to reach motor milestones such as sitting without support, rolling, crawling, standing unaided and walking independently.
   Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics'' Board of Directors  2021/06/09 12:00:00 PR Newswire
SOUTH PLAINFIELD, N.J., June 9, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Mary L. Smith to the Company''s Board of Directors. Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health Service, a
   William Blair Thinks PTC Therapeutics Stock is Going to Recover  2021/06/03 08:06:48 Smarter Analyst
In a report released today, Raju Prasad from William Blair maintained a Buy rating on PTC Therapeutics (PTCT). The companys shares closed last The post William Blair Thinks PTC Therapeutics Stock is Going to Recover appeared first on Smarter Analyst .
   PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia  2021/05/26 00:00:00 BioSpace
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation (ODD) for PTC923 for the treatment of patients with hyperphenylalaninemia. Phenylketonuria (PKU) accounts for 98% of all hyperphenylalaninemia cases and is a metabolic condition that can lead to cognitive disabilities and seizures
   The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data  2021/05/04 12:10:20 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV ) BioNTech SE – ADR (NASDAQ: BNTX ) (moving on momentum imparted by vaccine news flow) GT Biopharma Inc (NASDAQ: GTBP ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Lantheus Holdings Inc (NASDAQ: LNTH ) Orthopediatrics Corp (NASDAQ: KIDS ) Quest Diagnostics Incorporated (NYSE: DGX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aptinyx Inc. (NASDAQ: APTX ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AVROBIO, Inc. (NASDAQ: AVRO ) (reacted to the need for conducting a registrational trial for its gene therapy candidate for Fabry disease) Aziyo Biologics, Inc. (NASDAQ: AZYO ) Celyad Oncology SA (NASDAQ: CYAD ) Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) Cyclerion Therapeutics, Inc. (NASDAQ: CYCN ) Decibel Therapeutics, Inc.
   The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx  2021/04/29 12:15:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 28) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) IRadimed Corporation (NASDAQ: IRMD ) Lucira Health, Inc. (NASDAQ: LHDX ) Mesoblast Limited (NASDAQ: MESO ) Protara Therapeutics, Inc. (NASDAQ: TARA ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Stocks In Focus Adverum Shares Sink On Serious Adverse Event Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema.
   RBC Capital Stick to Their Hold Rating for PTC Therapeutics By Investing.com  2021/04/12 01:46:44 Investing.com
RBC Capital Stick to Their Hold Rating for PTC Therapeutics
   PTC Therapeutics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/02/24 14:28:00 Stock Market Daily
PTC Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   RBC Capital Stick to Their Sell Rating for PTC Therapeutics By Investing.com  2021/01/14 09:09:21 Investing.com
RBC Capital Stick to Their Sell Rating for PTC Therapeutics
   PTC Therapeutics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/02/24 14:28:00 Stock Market Daily
PTC Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   RBC Capital Stick to Their Sell Rating for PTC Therapeutics By Investing.com  2021/01/14 09:09:21 Investing.com
RBC Capital Stick to Their Sell Rating for PTC Therapeutics
   Duchenne Muscular Dystrophy (DMD) Treatment Market Latest Insights By Major Key Players SUMMIT Therapeutics Plc., PTC Therapeutics, BioMarin Pharmaceuticals Incorporated, Sarepta Therapeutics, Pfizer Incorporated, Pharmacia & Upjohn LLC  2021/01/14 06:14:40 OpenPR
The Duchenne Muscular Dystrophy (DMD) Treatment Market is expected to have a highly positive outlook over the forecast period 2020-2027 according to a Duchenne Muscular Dystrophy (DMD) Treatment Market research report. The Duchenne Muscular Dystrophy (DMD) Treatment report stresses the
   Ptc Therapeutics Inc (PTCT) CEO Stuart Walter Peltz Sold $1.2 million of Shares  2020/12/10 02:15:05 Yahoo Finance
CEO of Ptc Therapeutics Inc (30-Year Financial, Insider Trades) Stuart Walter Peltz (insider trades) sold 20,017 shares of PTCT on 12/07/2020 at an average price of $61.42 a share.
   PTC Therapeutics Reviews Inducement Grants Below Nasdaq Itemizing Rule 5635(c)(4)  2020/12/05 00:54:12 Fintech Zoom
PTC Therapeutics Reviews Inducement Grants Below Nasdaq Itemizing Rule 5635(c)(4) -

calendar